Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 128,898

Document Document Title
WO/2018/042018A2
The present invention relates to an approach for the treatment of adverse neurological sensations in a certain body surface area such as the skin, in particular treatment of pain or itching. The invention is based on the finding that adm...  
WO/2018/042423A1
The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long ...  
WO/2018/042384A1
Compositions comprising extracts prepared from mixtures of the herbal plants Radix Bupleurum chinense DC ("B"), Rhizoma Corydalis yanhusuo WT Wang ("Y"), Caulis Polygonum multiflorum Thunb ("P") and Flos Albizia julibrissin Durazz ("A") ...  
WO/2018/045250A1
Provided herein are methods of treating a disease, such as Parkinson's disease, that is due to increased poly [ADP-ribose] polymerase 1 (PARP-1) activation, by inhibiting macrophage migration inhibitory factor (MIF) nuclease activity.  
WO/2018/042182A1
The present invention relates to compositions for use in the treatment, prevention or management of neurological degeneration or dementia, comprising inhibitors or antagonists of monomeric C-reactive protein (mCRP), and optionally, the i...  
WO/2018/041812A1
The present invention relates to the field of neurodegenerative diseases, and the prevention and/or treatment of TBC1D24-associated disorders, such as DOORS syndrome, (intractable) epilepsy, and nonsyndromic deafness. In particular, the ...  
WO/2018/041563A1
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes...  
WO/2018/042362A1
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/042096A1
The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indol-1-yl-(1H)quinolin-2-one and indol-3-yl-(1H)quin...  
WO/2018/045178A1
Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.  
WO/2018/043674A1
Provided are: a composition for activating neurogenesis; use of the same; and a method for preventing, improving, inhibiting the progress and/or treating disorders and the like of the central and/or peripheral nervous systems. The presen...  
WO/2018/040627A1
Use of catalpol in preparation of a drug for preventing and treating or delaying the onset of myasthenia and/or amyotrophy, including myasthenia and/or amyotrophy caused by diabetes, and myasthenia and/or amyotrophy caused by defect of d...  
WO/2018/043714A1
The purpose of the present invention is to efficiently produce microglia from a pluripotent stem cells. Provided is a method for producing microglia from pluripotent stem cells, comprising the following steps: (a) a step of co-culturing ...  
WO/2018/045276A8
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/042362A9
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/041269A1
Disclosed are a transdermal administration formulation system for delivering a specific nanobody biomedicine through skin tissue and a preparation method and the use thereof. By optimizing the formulation of the carrier, and maintaining ...  
WO/2018/045083A1
Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual ...  
WO/2018/045276A1
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/045045A1
Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substi...  
WO/2018/041919A1
The present invention relates to a compound of the following formula (A): or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a disease associated with a mitochondrial dysfunction.  
WO/2018/039378A1
This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disub...  
WO/2018/035616A1
Provided are novel peptides of Formula SEQ ID No. 1: J1CysX1X2X3X4X5X6ProX7ThrCysJ2J3(J4)s(J5)t; (SEQ ID No. 1) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are which are effective inhibitors ...  
WO/2018/039147A1
Described are methods of inhibiting neurodegeneration in a subject by administering to the subject an agent that prevents (alpha)-syn PFF from binding to its receptor. The agent may be a small molecule chemical compound, antibody, nuclei...  
WO/2018/036080A1
The invention provides an application of an amino adamantane mononitrate in preparing a drug for preventing and treating diseases such as glaucoma, vascular dementia, subarachnoid hemorrhage, pulmonary arterial hypertension, and the like...  
WO/2018/039642A1
Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof...  
WO/2018/038022A1
Provided is a means whereby the skin permeability of rivastigmine can be improved without adversely affecting the adhesiveness of a patch. A non-aqueous patch comprising a support, a drug-containing adhesive layer and a release liner, wh...  
WO/2018/035751A1
A Cordyceps sinensis health supplement containing traditional Chinese medicine extracts and a preparation method therefor. The health supplement comprises the following raw materials in parts by weight: 20-40 parts of Folium Mori extract...  
WO/2018/039062A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful as a BACE1 inhibitor.  
WO/2018/038599A1
The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or...  
WO/2018/038265A1
The present invention provides: a novel use of a specific bicyclic nitrogenated heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogenated heterocyclic compound having a PDE7 inhibition activity, a method for producing the ...  
WO/2018/039190A1
A kit for treating psychosis by administering a pharmaceutically acceptable liquid composition of Asenapine to oral mucosa includes a formulation having Asenapine, or a pharmaceutically acceptable salt or hydrate thereof, ethanol, and wa...  
WO/2018/038255A1
The purpose of the present invention is to provide crystals of a compound that exhibits an analgesic action against neuropathic pain and/or fibromyalgia, the crystals being useful as pharmaceuticals. The present invention provides crysta...  
WO/2018/039526A1
Methods for managing pain, treating pain, and treating neurodegenerative disorders. The methods include administering to a subject in need thereof: (A) a therapeutically effective amount of simvastatin or a pharmaceutically acceptable sa...  
WO/2018/039159A1
A combination of a M2-receptor antagonist and a non-anticholinergic antiemetic agent, and optionally an anticholinesterase inhibitor, to treat hypocholinergic disorders such as Alzheimer type dementia, schizophrenia, schizophrenia associ...  
WO/2018/037306A1
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfen...  
WO/2018/038973A1
Peptide analogues of β-amyloid and methods of using said analogues for neuroprotection are described herein. The β-amyloid peptide analogues have a sequence that is at least 50% identical to an N-terminal β-amyloid core fragment. A ph...  
WO/2018/039545A2
Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 dom...  
WO/2018/033149A1
Provided are crystal forms of Ozanimod and a preparation method therefor. The provided crystal forms of Ozanimod comprise a crystal form CS9, a crystal form CS10, and a crystal form CS11 of Ozanimod, and can be used for treating autoimmu...  
WO/2018/034345A1
The present invention pertains to a composition for improving peripheral neuropathy caused by the administration of anticancer agents, the composition comprising a milk protein hydrolysate and protein derived from fermented milk as prote...  
WO/2018/034330A1
The purpose of the present invention is to provide a novel composition for promoting ketone body formation. The present invention provides a composition for promoting ketone body formation, the composition containing one or more amino ac...  
WO/2018/032611A1
A neuroprotective agent, comprising a compound as represented by formula (I).  
WO/2018/035477A1
The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to...  
WO/2018/033525A1
This invention relates to compounds that are agonists or partial agonists of the histamine site of the NMDA receptor, the method of preparation thereof and applications thereof.  
WO/2018/033848A1
The present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the ...  
WO/2018/035157A1
The present application relates to novel compositions useful for the treatment of a neurodegenerative disease and uses thereof. The present application also relates to novel compositions and methods for the reduction of side effects in a...  
WO/2018/033911A1
A method of treating a neurological disease (such as autism) in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of microparticles derived from mesenchymal stem cells.  
WO/2018/033847A1
The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically accepta...  
WO/2018/033724A1
The invention relates to neurodegenerative disorders, and in particular to novel peptides, peptidomimetics, compositions, therapies and methods for treating such conditions, for example Alzheimer's disease.  
WO/2018/033841A1
The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance r...  
WO/2018/034023A1
The present invention relates to a life extension agent comprising CD24-negative mesenchymal stem cells, and a therapy using the life extension agent, the therapy being for dementia, cerebral infarction, spinal cord injury, and the like.  

Matches 251 - 300 out of 128,898